Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response

Roland Lang, Michael Hammer and Jörg Mages
J Immunol December 1, 2006, 177 (11) 7497-7504; DOI: https://doi.org/10.4049/jimmunol.177.11.7497
Roland Lang
Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Immunology and Hygiene, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hammer
Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Immunology and Hygiene, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörg Mages
Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Immunology and Hygiene, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The MAPK family members p38, JNK, and ERK are all activated downstream of innate immunity’s TLR to induce the production of cytokines and inflammatory mediators. However, the relative intensity and duration of the activation of different MAPK appears to determine the type of immune response. The mammalian genome encodes a large number of dual specificity phosphatases (DUSP), many of which act as MAPK phosphatases. In this study, we review the emergence of several DUSP as genes that are differentially expressed and regulated in immune cells. Recently, a series of investigations in mice deficient in DUSP1, DUSP2, or DUSP10 revealed specificity in the regulation of the different MAPK proteins, and defined essential roles in models of local and systemic inflammation. The DUSP family is proposed as a set of molecular control devices specifying and modulating MAPK signaling, which may be targeted to unleash or attenuate innate and adaptive immune effector functions.

Innate immune cells respond swiftly to the presence of specific ligands signaling infectious danger that they recognize through pattern recognition receptors. Activation of TLR, e.g., by LPS of Gram-negative bacteria, lipopeptides derived from Gram-positive bacteria or immunostimulatory CpG DNA, induces the expression of cytokines, chemokines, and other inflammatory mediators within less than 1 h. Two major signaling pathways are activated downstream of the TLR-induced Myd88-IL-1R-associated kinase-TNFR-associated factor 6 complex, which are essential for such a rapid response, and both involve the activation of latent transcription factors as follows: 1) activation of the IκB kinase complex targets IκB for degradation leading to nuclear translocation of active NF-κB; and 2) the MAPK pathway, a cascade of phosphorylation events that primarily results in the posttranslational activation of transcription factors like CREB and AP-1. Both pathways synergize in inflammatory gene expression through coordinate binding of transcription factors to κB and AP-1 sites found together in the promoters of e.g., Il6, Tnfa, and many other genes that are up-regulated in response to TLR ligation.

The three major subfamilies of MAPK that are expressed in the immune system are p38, ERK, and JNK (1). All three MAPK are phosphorylated on the threonine and tyrosine residues of the shared TxY motif within minutes after TLR stimulation of macrophages and dendritic cells (DC)3, as shown early on for the TLR4 ligand LPS (2) and CpG DNA that activates TLR9 (3, 4). Rapid transduction of the signal from TNFR-associated factor 6 to the MAPK is achieved through the sequential activation of upstream MAP3K and MAPK kinases (reviewed in Ref. 1).

Downstream of the MAPK, a large number of substrates that are serine/threonine-phosphorylated have been defined, including transcription factors of the ATF/CREB and AP-1 family, kinases such as Mapkapk2/MK2 and RSK, and proteins controlling mRNA stability and translation. Although there is some overlap in the target proteins of MAPK, prototypic-specific downstream mediators have also been defined using specific pharmacological inhibitors. These studies demonstrated the importance of MAPK activation in cytokine and chemokine gene expression in general, and provided many specific examples of genes that are regulated preferentially by one or the other MAPK. For example, IL-10 production was inhibited by the Map2k1/MEK1 inhibitor U0126 (5, 6), whereas IL-12 expression was suppressed by inhibition of p38 with SB203580 (5, 7). Furthermore, higher IL-12 production from DC than from macrophages after stimulation was inversely correlated with differences in the amount of ERK activation between the cell types (8). The concept that the pattern of MAPK activation may determine the type of cytokine output was further supported by investigations into the activation of MAPK by different TLR ligands inducing reciprocal patterns of secretion of the immunosuppressive cytokine IL-10 and the Th1-driving IL-12 (9, 10). High levels of IL-10 along with low IL-12 production in response to TLR2 stimulation were shown to correlate with strong ERK activation, whereas TLR4, TLR5, or TLR9 ligands preferentially activated p38 and induced more IL-12 (9, 10). Through the use of ERK1- and Fos-deficient macrophages, a pathway could be delineated that controls the ratio of IL-10 vs IL-12 production with strong ERK activity stabilizing and enhancing the transcription of Fos that in turn supports IL-10 production and inhibits IL-12 (11). Similar conclusions could be made from studies showing Th-2 type adjuvant activity of TLR2 ligands in vivo (12) and IL-10-promoting effects of ERK-activation by Leishmania phosphoglycans (13). Thus, the MAPK pathway is used in innate immunity not only to deliver the alarm signals from TLR on fast-track to the nucleus, but also it provides a means to translate the nature of the stimulus into appropriate responses by balancing the strength of individual MAPK signals. The impact of this preferential activation, and the notion that in addition to the intensity the kinetics of MAPK activation will determine the cellular response to stimulation, leads us to the question how MAPK activation is inhibited or terminated.

Down-regulation of MAPK signaling: dual specificity phosphatases (DUSP) and other MAPK phosphatases (MKP)

Inactivation of MAPK occurs primarily through dephosphorylation of the TxY motif. Because MAPK have to be phosphorylated on both threonine and tyrosine residues for kinase activity, inactivation can be brought about by members of different phosphatase families. MKP include serine-threonine phosphatases (PP2A and PP2C), the tyrosine phosphatases PTPN5, PTPN7, and PTPRR (14, 15), and members of the DUSP family that is the focus of this study. (A confusing number of synonyma exists for some of the DUSP genes or proteins. We advocate the use of the official gene symbol that is also the abbreviation of the protein. In Table I⇓ and on first appearance in the text, the most common synonyms are also given.) All DUSP genes encode a catalytic domain harboring a signature HCxxxxxR motif. Of the 30 protein-coding DUSP genes found in the human genome (16), 11 are bona fide MKP because in addition to the DUSP domain they contain a MAPK binding domain (MKB). The 19 atypical DUSP are much smaller proteins that lack such a MKB, but may still function as MKP as already demonstrated for DUSP14/MKP6 (17), DUSP3/VHR (18), and DUSP22/VHX (19). Although more atypical DUSP may turn out to deactivate MAPK, most seem to have unrelated substrates including RNA in the case of DUSP11/PIR (16).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Classification of DUSP MKP

The biochemistry and structural biology of DUSP proteins have been recently reviewed (15, 20) and are therefore touched on in this study only briefly. The presence or absence of MKB, DUSP, and additional N- or C-terminal domains provides a reasonable basis for grouping DUSP-MKP into four different types (Table I⇑) (15). The subcellular localization and preference for one or the other MAPK as a substrate have also been used to subdivide the DUSP family (14, 20); however, these are not always well-defined and may depend on cell-type, activation state, and the presence of interacting proteins.

The 3D structure of the catalytic DUSP domain has been solved for DUSP6/MKP-3, DUSP2/PAC-1, and DUSP3/VHR, revealing that for the atypical DUSP3 it is in a catalytically active conformation (reviewed in Ref. 15). In contrast, in the absence of substrate, the catalytic domain of DUSP2 and DUSP6 is in a disordered state. As shown for DUSP6, binding to the substrate ERK2 MAPK then strongly increases the catalytic activity (21). The type III MKP DUSP10/MKP-5 contains a unique N-terminal domain of unknown function that is suspected to contain regulatory sites (22). In contrast to DUSP6, the catalytic activity of DUSP10 is not increased by binding to p38 or JNK (22). The larger type IV MKP DUSP8/VH5 and DUSP16/MKP-7 have a C-terminal region with a number of interesting features including proline/glutamine/serine/threonine rich, nuclear localization, and leucine-rich nuclear export sequences that play a role in stability of the protein, interaction with scaffold proteins, and control nuclear-cytoplasmic shuttling of the protein (23, 24, 25, 26, 27).

Patterns of DUSP expression: changes during development, between cell types, and in response to external stimuli

In contrast to their substrate MAPK that are expressed ubiquitously, many DUSP genes show regulated expression during development, in a cell type-specific manner or in response to cellular activation. A good example for the latter is the prototypic MKP, DUSP1/MKP-1, that was cloned as immediate-early gene 3CH134 from serum stimulated human fibroblasts (28, 29). Similarly regulated by growth factors or in response to cell stress are DUSP2/PAC1, DUSP4/MKP-2, and DUSP5/VH3. DUSP9/MKP-4 is highly expressed in the developing liver and placenta, but at low levels in other organs, illustrating developmentally regulated expression (30, 31).

The availability of microarray technologies was the prerequisite for the identification of DUSP as differentially regulated genes under many different experimental conditions through large scale gene expression profiling. Individual DUSP were found up-regulated in various cancers, in response to hypoxia, heat shock, and other perturbations of cells and tissues. Of importance, DUSP have surfaced in several studies investigating innate and adaptive immune responses. Kovanen et al. (32, 33) analyzed T cell transcriptional responses to cytokine signaling through the common γ-chain and identified DUSP5/VH3 and DUSP6/MKP-3 as up-regulated by IL-2, IL-7, and IL-15. Tanzola and Kersh (34) performed a real-time PCR profile of DUSP expression during thymic development that showed expression and regulation of 7 of 10 DUSP genes at various stages of T cell development and following stimulation of the TCR complex. In a comprehensive microarray experiment of human leukocyte subsets, Jeffrey et al. (35) analyzed the regulation of DUSP genes following activation of B cells, T cells, mast cells, eosinophils, macrophages, and DC, and found high levels of induction for the nuclear MKP DUSP1, DUSP2, DUSP4, and DUSP5 in activated immune cells. Mining of transcriptome datasets from primary mouse macrophages stimulated with LPS or the RAW 264.7 macrophage cell line after activation with a set of TLR ligands, our laboratory identified DUSP1, DUSP2, and DUSP16 as the most strongly induced MKP; thus, there is substantial overlap between these studies in the human and mouse system (36, 37). Finally, genome-wide analyses of the host pathogen interaction have revealed induction of several DUSP family members in macrophages infected with mycobacteria (38), Gram-negative and -positive bacteria (39), and virus-infected HeLa cells (40).

Defining essential functions for DUSP in immunity: the examples of DUSP1, DUSP10, and DUSP2

During the first decade of research into DUSP-MKP, the biochemistry of the interaction with MAPK was elucidated for some members in great detail. Much less is known about the physiological roles of the individual DUSP, which is only beginning to be revealed through the generation and phenotypic analysis of gene-targeted mice. Given the large number of DUSP-MKP, often coexpressed in one cell type, redundancy and functional compensation could be expected when just a single DUSP gene is inactivated. As reviewed in the following sections, for the DUSP-KO mice studied in immunological models to date, strong phenotypes were observed that suggest a surprising degree of nonredundancy in the function of individual DUSP genes (Table II⇓).

View this table:
  • View inline
  • View popup
Table II.

Immunologically relevant DUSP family members

DUSP1/MKP-1: from no phenotype to molecular brake in inflammation

The first DUSP MKP was discovered as immediate early gene in the fibroblast serum response and initially thought to dephosphorylate ERK and only later shown to deactivate MAPK in the order p38>JNK≫ERK (41). This initial misconception may also underlie the failure to investigate the effect of DUSP1-deficiency on the different MAPK more closely in the first description of gene targeted mice. From the apparent health of the mice and the unaltered kinetics of ERK activation, it was concluded that DUSP1 does not have nonredundant functions (42). Indeed, a recent analysis of MEFs from DUSP1−/− mice showed enhanced phosphorylation of p38 and JNK, but not ERK, after osmotic stress and anisomycin, that caused increased cell death (43).

DUSP1/MKP-1 is expressed in many hemopoietic and epithelial cell types, and up-regulated in response to hypoxia (44), heat shock (45), several growth factors, and in various malignancies. In macrophages, the first detection of DUSP1 mRNA was reported in Listeria-infected cells (46). Celada and colleagues (47, 48) then showed that DUSP1 is induced by signaling through the M-CSF receptor as well as in response to LPS, and additionally demonstrated the involvement of PKC in this process. TLR stimuli increase DUSP1 expression through MyD88- or, in the case of poly(I:C), TRIF-dependent signaling (49). Whether DUSP1 is a NF-κB-dependent target of TLR signaling has not been addressed. MAPK signaling controls DUSP1 expression at various levels. In fibroblasts, activation of the JNK pathway, but not of ERK, resulted in increased DUSP1 mRNA (50). Similarly, inhibition of MEK-1 by PD98059 did not interfere with LPS-induced expression of DUSP1 in macrophages (47, 48). However, the role of ERK signaling in DUSP1 mRNA expression is not entirely clear, because the MEK-1 inhibitor U0126 was reported to block LPS-induced increases of DUSP1 at the mRNA and protein level (51). Although TLR signaling activates the DUSP1 promoter, mRNA levels may also be controlled by prolonging the very short half-life of the transcript (36). ERK-dependent signals also increase the stability of DUSP1 protein through phosphorylation (52, 53). Consistent with a negative regulatory function for DUSP1 in macrophage activation, anti-inflammatory glucocorticoids increase DUSP1 expression in macrophages, and mast cells at the mRNA and protein level (36, 54, 55, 56). Recently, we found (36) that the immunosuppressive cytokine IL-10 enhanced and prolonged DUSP1 expression in TLR-stimulated macrophages, acting in synergy with dexamethasone. Finally, the anti-inflammatory effects of the endocannabinoid anandamide on microglia have recently been correlated to up-regulation of DUSP1 protein levels, suggesting that signaling through the CB2 receptor is another pathway that leads to dampened MAPK activation through increased DUSP1 levels (57).

A negative effect of DUSP1 on macrophage activation was suggested by overexpression of DUSP1, which was shown in a number of studies to inhibit phosphorylation of MAPK and the production of the cytokines TNF-α and IL-6 in response to diverse TLR stimuli (51, 55, 58). A requirement for DUSP1 as a physiological regulator of MAPK activation and cytokine production in macrophages was then demonstrated by a series of studies that used DUSP1−/− mice generated in the Bravo laboratory (49, 59, 60), or an independently created DUSP1−/− mouse line (61). Together, these studies show that p38 MAPK is the primary target of DUSP1 in activated macrophages, followed by JNK with no or very little effect on ERK activation. DUSP1-deficient macrophages secrete increased amounts of TNF-α, IL-6, and IL-10 after stimulation with TLR-ligands. In the high-dose LPS shock model in vivo, the absence of DUSP1 renders mice highly susceptible to the lethal effects of endotoxin, with a corresponding, substantially elevated production of certain cytokines and mediators. Consistent with the lethal outcome, DUSP1−/− mice displayed the hallmarks of septic shock, such as depressed circulation, kidney failure, and inflammatory infiltrates in the lung and other tissues, much more pronounced than the surviving wild-type mice (60). Salojin et al. (61) further demonstrated in a model of autoimmune disease that collagen-induced arthritis is markedly more severe in DUSP1-deficient mice, with increased joint swelling and production of IL-6 and TNF-α. DUSP1 is therefore an essential endogenous negative regulator of the systemic and local innate inflammatory response, phenotypically similar in effect to the cytokine IL-10 (62, 63) or the phosphatase SHIP (64). Of note, however, not all cytokine and chemokine responses to the challenge with LPS are dysregulated in the absence of DUSP1, because serum levels of IFN-γ, IL-12p40, and IP-10 after LPS challenge were comparable or even reduced. Moreover, microarray analysis of spleen RNA revealed at the genome-wide level that DUSP1 controls a subset of LPS-induced genes (59, 60). An interesting aspect of these data is the counterintuitive, overwhelming release of IL-10 in the absence of DUSP1, which might be expected to bring about down-regulation of the inflammatory reaction but obviously fails to do so. Although elevated levels of known IL-10 induced genes (37) such as SOCS3, NFIL3, or Bcl-3 suggest intact IL-10 signaling in the absence of DUSP1, an essential fraction of IL-10-induced macrophage deactivation may therefore depend on functional DUSP1. The mutual regulation of expression between IL-10 and DUSP1 is connected in a module with p38 MAPK (Fig. 1⇓), whose contribution to IL-10 expression was also recently substantiated by work from the Ivashkiv and colleagues (6) laboratory.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Schematic overview: regulation of immune cell activation by DUSP1 (A), DUSP2 (B), and DUSP10 (C). Selectivity for the different MAPK and regulation of transcriptional responses are shown as described in the text. A, DUSP1 expression in macrophages is synergistically induced by TLR and IL-10 or glucocorticoid receptor signaling. DUSP1 acts primarily on p38 MAPK, thereby limiting the activity of CREB and AP-1 transcription factors and controlling the expression of a subset of LPS target genes. B, Control of JNK-ERK cross-talk by DUSP2 in mast cells and macrophages. DUSP2 is induced in macrophages by TLR ligands and in mast cells by FcεRI ligation. DUSP2 protein associates MAPKs and blocks JNK-mediated inhibition of ERK activation. In effect, DUSP2 increases expression of inflammatory genes in both cell types. C, Impact of DUSP10 on innate and adaptive immune cells. In macrophages (right), TLR ligands induce DUSP10 expression that inhibits JNK activity and thereby constrains the production of cytokines and may reduce costimulation of T cells. In T cells (left), DUSP10 is constitutively expressed and inhibits early JNK activation after TCR ligation. Increased JNK activity in the absence of DUSP10 results in reduced proliferation and increased AP-1-dependent production of T cell cytokines.

DUSP10/MKP-5: acting on innate and adaptive responses

DUSP10/MKP-5 is the only member of the type III group of DUSP-MKP, carrying an additional N-terminal domain of poorly characterized function that may control its cytoplasmic or nuclear location (22). JNK and p38 MAPK appear to be the preferred substrates of DUSP10 (22). Although DUSP10 is expressed at much lower levels in immune cells compared with many other DUSP, as judged from microarray data, gene targeting in mice revealed an interesting phenotype with distinct functions for DUSP10 in innate, and adaptive immunity (Fig. 1⇑) (65). DUSP10 is inducible by TLR stimulation in macrophages, which showed increased activation in its absence in terms of elevated cytokine production in vitro and in vivo, although the difference does not seem to be as big as in DUSP1−/− mice. In CD4+ T cells, DUSP10 is constitutively expressed but down-regulated 24 h after TCR activation. In the absence of DUSP10, Th cells activate JNK more strongly early after activation. Although DUSP10-deficient T cells produced strikingly increased amounts of both Th1 and Th2 cytokines, their Ag-specific proliferation was impaired, consistent with an inhibitory role for JNK on T cell growth observed earlier (66). Impaired T cell expansion in DUSP10-deficient mice is also the likely cause of an amelioration of disease symptoms in the MOG-induced EAE model, where brain infiltration by Th cells was abrogated nearly completely. Finally, in viral lymphocytic choriomeningitis virus (LCMV) infection, strongly enhanced production of the T cell-derived cytokines IL-2, IFN-γ, IL-4, and TNF-α upon secondary infection resulted in the immune-mediated death of DUSP10-deficient mice. Contrary to what might be expected given the reduced proliferation of T cells in vitro, the frequency of LCMV-reactive CD8 and CD4 T cells was not reduced in the absence of DUSP10. This discrepancy may be explained by the increased APC function of DUSP10−/− innate immune cells that compensated for T cell autonomous growth-inhibitory effects (Fig. 1⇑).

DUSP2/PAC1: from feedback inhibition to driving force of inflammation

Cloned in 1993 as an immediate early gene from TCR-activated T cells (67), DUSP2/PAC-1 localizes to the nucleus and primarily inactivates p38 MAPK and ERK in vitro (68). DUSP2 was found expressed in malignant tissues where high levels correlated with poor prognosis (69). It was also described as a transcriptional target of p53 that is required for the induction of apoptosis in a colon cancer cell line (70). In another study, DUSP2 expression was found to be controlled by ERK activation (71). In nontransformed cells, the expression of DUSP2 appears to be restricted predominantly to the hemopoietic lineages, where it is highly inducible in macrophages, mast cells, eosinophils, B, and T cells by activation of Ag or Fc receptors (35). This distinguishing feature of DUSP2 may already indicate a special function for this phosphatase in immune cells. Indeed, the recently reported (35) phenotype of the DUSP2−/− mouse confirmed a significant role in the immune system, although the results contradicted expectations and introduced new twists into the tale of MAPK regulation by DUSP-MKP. Similarly to what was observed in the case of DUSP1 or DUSP10, the immune system of DUSP2−/− mice develops normally. Contrasting to the effects of DUSP1 and DUSP10 deficiency, DUSP2−/− macrophages and mast cells produced fewer inflammatory mediators after stimulation via TLR and FcεR, respectively. In addition, DUSP2−/− mast cells failed to proliferate long term, which was due to an increased rate of apoptosis. In harmony with this impaired responsiveness in vitro, DUSP2−/− mice were protected in the K/BxN arthritis model that particularly depends on the effector functions of mast cells and macrophages.

How can this surprising positive effect of DUSP2 be explained at the molecular level? From overexpression studies in vitro, DUSP2 appeared to dephosphorylate p38 and ERK (68). However, in the absence of DUSP2, a decreased or shortened activation of these MAPK was observed in macrophages and mast cells. A reduced activation of Elk- and AP-1 reporter genes showed the functional significance of reduced ERK activation in DUSP2−/− cells. In contrast, JNK activation was increased and the use of JNK inhibitors rescued ERK phosphorylation and Elk reporter gene activation, suggesting that DUSP2 strengthens ERK activation by blocking JNK. Finally, the authors also showed that DUSP2 physically interacts with p38, JNK, and ERK, providing a basis for the cross-talk between MAPK that is suggested by the data (Fig. 1⇑). Such a negative cross-talk relationship between JNK and the ERK pathway had been previously described, seemingly dependent on Jun-induced gene expression (72). It is worth mentioning that a positive regulatory role for a DUSP in MAPK activation is not without precedent, as both human DUSP22/JSP-1 and its murine orthologue DUSP22/JKAP were found to specifically activate JNK upon overexpression (73, 74), and murine DUSP22 was indeed required for full activation of JNK in response to TNF-α (74). Together, these results are important in demonstrating that DUSP proteins not only inhibit biological responses by terminating MAPK activation, but also can decisively increase the activation of a specific MAPK.

Inclusion of DUSP in the equation: a more accurate description of MAPK driven immune activation

Recently, the field of signal transduction research has seen a growing appreciation of the specific and active roles of phosphatases in the regulation of physiological processes in general. This shift in attention from kinases to phosphatases was in part due to the realization that mammalian genomes encode a much larger number of phosphatases than previously thought. This is especially true in the case of the MAPK family, where the large family of DUSP MKP outnumbers the small group of MAPK. The inclusion of these regulators in the MAPK signaling module provides specification and flexibility in the downstream responses to MAPK-activating stimuli by introducing a number of additional variables. These include the following: 1) the set of constitutively expressed DUSP in a given cell that controls the initial response type; 2) the kinetics of inducible expression of DUSP as feedback inhibitors; 3) subcellular compartmentalization of negative regulation by the action of cytoplasmic and nuclear DUSP; and 4) DUSP-mediated cross-talk at the level of MAPK that can even result in positive effects on individual MAPK. DUSPs belong therefore to a larger group of molecules, including scaffold proteins and other inhibitors, that determine the subcellular localization, the intensity and the kinetics of differential MAPK activation in different cell types in response to various stimuli (75, 76).

The studies reviewed here demonstrate that DUSP fulfill an important function in innate and adaptive immune cell responses. Following the identification of different DUSP as genes differentially expressed and regulated in immune cells, the modulation and specification of immune receptor initiated MAPK signaling by this family of MKP is being revealed in ongoing biochemical and genetic studies in the mouse model. It is likely that phenomena of differential MAPK activation and biological responses to different stimuli or by different cell types may, at least in part, be attributable to the action of DUSP. For example, the findings that the balance between p38 and ERK activation in DC in response to TLR triggering determines the relative strength of immunosuppressive IL-10 or Th1-driving IL-12 production (9, 10) may be explained by regulated expression patterns of DUSP family members. DUSP1−/− macrophages have increased p38 MAPK activation whereas ERK phosphorylation is unchanged, but contrary to what might be expected this leads to elevated production of IL-10 but not of IL-12 (59, 65). Therefore, the equations that translate expression levels of DUSP and activation states of MAPK into transcriptional responses may not be that simple. There is now a need to investigate the contribution of individual DUSP to the regulation of the MAPK module in inflammation and infection, and thereby generate the data necessary to establish these rules.

Impact of DUSP on other signaling pathways?

Another important question for future study is whether and how DUSP interfere with other signaling pathways, be it indirectly via changes in MAPK activity or directly by acting on additional substrates. At the moment, there is no evidence for direct binding and dephosphorylation of non-MAPK targets by the classical DUSP MKP that contain a MKB domain. This is different for the atypical DUSP that can dephosphorylate a wide array of target proteins and even RNA. It would therefore not be too surprising if one or the other of the classical DUSP MKP would also turn out to bind and inactivate novel targets. An indirect impact of the DUSP family is expected for pathways that are already known to cross-talk with the MAPK module. For example, p38-dependent histone modifications and chromatin remodeling in macrophages and DC after TLR stimulation facilitates access of NF-κB transcription factors to the promoters of certain cytokines and chemokines (77). We have observed that NF-κB binding sites are overrepresented in the promoters of DUSP1-contolled LPS-responsive genes, although there was no detectable difference in IκB degradation and nuclear translocation of RelA p65, implying that stronger p38 activation in the absence of DUSP1 may increase the recruitment of NF-κB transcription factors to the promoters of these genes (our unpublished data). Serine phosphorylation of STAT1 mediated by p38 MAPK represents another example of cross-talk that may be indirectly controlled by DUSP proteins and contribute to the shaping of the transcriptional responses (78, 79). Curiously, there are reports from two different groups suggesting that DUSP1 dephosphorylates STAT1 at tyrosine residues in hepatocytes and vascular smooth muscle cells, which would imply a more direct interaction with the JAK-STAT pathway (80, 81). However, these claims were contested by a yeast two hybrid-based investigation of DUSP1 binding determinants that concluded that direct interactions are limited to the MAPK family (82).

DUSP as targets for the manipulation of immune responses?

The phenotypic analysis of DUSP-deficient mice has already shown their importance in regulating immune responses in a few models of systemic and local inflammation. These mouse lines provide ideal tools to investigate the function of DUSP family members in additional models of autoimmune diseases. Likewise, the impact of DUSP on the host response to infection can now be investigated using a range of different pathogens. Because bacterial and viral pathogens induce DUSP1 expression (38, 40), a lack of this presumable immune evasion mechanism may be expected to shift the balance in these infections to a more robust protective response. It is an important question whether changes in the production of inflammatory cytokines and mediators depending on the functionality of DUSP confer a state of more efficient pathogen control to the innate immune system, or may in contrast lead to increased immunopathology. Because DUSP bring about the specification of MAPK signaling, targeting of this class of regulators may perhaps enable us to dissociate desirable protective responses from self-destructive inflammation.

Acknowledgments

We thank Reinhard Hoffmann for critical reading of the manuscript.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 The work performed in the Lang laboratory was supported by the Deutsche Forschungsgemeinschaft (SFB 576, TP 11 and Grant LA 1262/4-1) and the Bundesministerium für Bildung und Forschung (NGFN-2 Grant 01GS0402).

  • ↵2 Address correspondence and reprint requests to Dr. Roland Lang, Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Immunology and Hygiene, Trogerstrasse 30, Munich 81675, Germany. E-mail address: Roland.Lang{at}lrz.tum.de

  • ↵3 Abbreviations used in this paper: DC, dendritic cell; MKP, MAPK phosphatase; DUSP, dual specificity phosphatases; MKB, MAPK binding domain; LCMV, lymphocytic choriomeningitis virus.

  • Received July 18, 2006.
  • Accepted August 28, 2006.
  • Copyright © 2006 by The American Association of Immunologists

References

  1. ↵
    Dong, C., R. J. Davis, R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
    OpenUrlCrossRefPubMed
  2. ↵
    Han, J., J. D. Lee, L. Bibbs, R. J. Ulevitch. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Hacker, H., H. Mischak, T. Miethke, S. Liptay, R. Schmid, T. Sparwasser, K. Heeg, G. B. Lipford, H. Wagner. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17: 6230-6240.
    OpenUrlAbstract
  4. ↵
    Yi, A. K., A. M. Krieg. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161: 4493-4497.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Yi, A. K., J. G. Yoon, S. J. Yeo, S. C. Hong, B. K. English, A. M. Krieg. 2002. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J. Immunol. 168: 4711-4720.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Hu, X., P. K. Paik, J. Chen, A. Yarilina, L. Kockeritz, T. T. Lu, J. R. Woodgett, L. B. Ivashkiv. 2006. IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24: 563-574.
    OpenUrlCrossRefPubMed
  7. ↵
    Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544.
    OpenUrlCrossRefPubMed
  8. ↵
    Hacker, H., H. Mischak, G. Hacker, S. Eser, N. Prenzel, A. Ullrich, H. Wagner. 1999. Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. EMBO J. 18: 6973-6982.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Dillon, S., A. Agrawal, T. Van Dyke, G. Landreth, L. McCauley, A. Koh, C. Maliszewski, S. Akira, B. Pulendran. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172: 4733-4743.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, B. Pulendran. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171: 4984-4989.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Pulendran, B.. 2005. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174: 2457-2465.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Redecke, V., H. Hacker, S. K. Datta, A. Fermin, P. M. Pitha, D. H. Broide, E. Raz. 2004. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 172: 2739-2743.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Feng, G. J., H. S. Goodridge, M. M. Harnett, X. Q. Wei, A. V. Nikolaev, A. P. Higson, F. Y. Liew. 1999. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J. Immunol. 163: 6403-6412.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Keyse, S. M.. 2000. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12: 186-192.
    OpenUrlCrossRefPubMed
  15. ↵
    Farooq, A., M. M. Zhou. 2004. Structure and regulation of MAPK phosphatases. Cell. Signal. 16: 769-779.
    OpenUrlCrossRefPubMed
  16. ↵
    Alonso, A., J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, T. Mustelin. 2004. Protein tyrosine phosphatases in the human genome. Cell 117: 699-711.
    OpenUrlCrossRefPubMed
  17. ↵
    Marti, F., A. Krause, N. H. Post, C. Lyddane, B. Dupont, M. Sadelain, P. D. King. 2001. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J. Immunol. 166: 197-206.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Alonso, A., S. Rahmouni, S. Williams, M. van Stipdonk, L. Jaroszewski, A. Godzik, R. T. Abraham, S. P. Schoenberger, T. Mustelin. 2003. Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat. Immunol. 4: 44-48.
    OpenUrlCrossRefPubMed
  19. ↵
    Alonso, A., J. J. Merlo, S. Na, N. Kholod, L. Jaroszewski, A. Kharitonenkov, S. Williams, A. Godzik, J. D. Posada, T. Mustelin. 2002. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J. Biol. Chem. 277: 5524-5528.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Theodosiou, A., A. Ashworth. 2002. MAP kinase phosphatases. Genome Biol. 3: Reviews3009
    OpenUrlPubMed
  21. ↵
    Camps, M., A. Nichols, C. Gillieron, B. Antonsson, M. Muda, C. Chabert, U. Boschert, S. Arkinstall. 1998. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280: 1262-1265.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Tanoue, T., T. Moriguchi, E. Nishida. 1999. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J. Biol. Chem. 274: 19949-19956.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Masuda, K., H. Shima, M. Watanabe, K. Kikuchi. 2001. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J. Biol. Chem. 276: 39002-39011.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Tanoue, T., T. Yamamoto, R. Maeda, E. Nishida. 2001. A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 α and β MAPKs. J. Biol. Chem. 276: 26629-26639.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Katagiri, C., K. Masuda, T. Urano, K. Yamashita, Y. Araki, K. Kikuchi, H. Shima. 2005. Phosphorylation of Ser-446 determines stability of MKP-7. J. Biol. Chem. 280: 14716-14722.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Willoughby, E. A., M. K. Collins. 2005. Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein β-arrestin 2. J. Biol. Chem. 280: 25651-25658.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Willoughby, E. A., G. R. Perkins, M. K. Collins, A. J. Whitmarsh. 2003. The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK. J. Biol. Chem. 278: 10731-10736.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Charles, C. H., H. Sun, L. F. Lau, N. K. Tonks. 1993. The growth factor-inducible immediate-early gene 3CH134 encodes a protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 90: 5292-5296.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Lau, L. F., D. Nathans. 1985. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 4: 3145-3151.
    OpenUrlPubMed
  30. ↵
    Christie, G. R., D. J. Williams, F. Macisaac, R. J. Dickinson, I. Rosewell, S. M. Keyse. 2005. The dual-specificity protein phosphatase DUSP9/MKP-4 is essential for placental function but is not required for normal embryonic development. Mol. Cell. Biol. 25: 8323-8333.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Dickinson, R. J., D. J. Williams, D. N. Slack, J. Williamson, O. M. Seternes, S. M. Keyse. 2002. Characterization of a murine gene encoding a developmentally regulated cytoplasmic dual-specificity mitogen-activated protein kinase phosphatase. Biochem. J. 364: 145-155.
    OpenUrlPubMed
  32. ↵
    Kovanen, P. E., L. Young, A. Al-Shami, V. Rovella, C. A. Pise-Masison, M. F. Radonovich, J. Powell, J. Fu, J. N. Brady, P. J. Munson, W. J. Leonard. 2005. Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes. Int. Immunol. 17: 1009-1021.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Kovanen, P. E., A. Rosenwald, J. Fu, E. M. Hurt, L. T. Lam, J. M. Giltnane, G. Wright, L. M. Staudt, W. J. Leonard. 2003. Analysis of γ c-family cytokine target genes: identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J. Biol. Chem. 278: 5205-5213.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Tanzola, M. B., G. J. Kersh. 2006. The dual specificity phosphatase transcriptome of the murine thymus. Mol. Immunol. 43: 754-762.
    OpenUrlCrossRefPubMed
  35. ↵
    Jeffrey, K. L., T. Brummer, M. S. Rolph, S. M. Liu, N. A. Callejas, R. J. Grumont, C. Gillieron, F. Mackay, S. Grey, M. Camps, et al 2006. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat. Immunol. 7: 274-283.
    OpenUrlCrossRefPubMed
  36. ↵
    Hammer, M., J. Mages, H. Dietrich, F. Schmitz, F. Striebel, P. J. Murray, H. Wagner, R. Lang. 2005. Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur. J. Immunol. 35: 2991-3001.
    OpenUrlCrossRefPubMed
  37. ↵
    Lang, R., D. Patel, J. J. Morris, R. L. Rutschman, P. J. Murray. 2002. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169: 2253-2263.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Blumenthal, A., J. Lauber, R. Hoffmann, M. Ernst, C. Keller, J. Buer, S. Ehlers, N. Reiling. 2005. Common and unique gene expression signatures of human macrophages in response to four strains of Mycobacterium avium that differ in their growth and persistence characteristics. Infect. Immun. 73: 3330-3341.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Nau, G. J., J. F. Richmond, A. Schlesinger, E. G. Jennings, E. S. Lander, R. A. Young. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99: 1503-1508.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Ludwig, H., J. Mages, C. Staib, M. H. Lehmann, R. Lang, G. Sutter. 2005. Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes. J. Virol. 79: 2584-2596.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Franklin, C. C., A. S. Kraft. 1997. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J. Biol. Chem. 272: 16917-16923.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Dorfman, K., D. Carrasco, M. Gruda, C. Ryan, S. A. Lira, R. Bravo. 1996. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13: 925-931.
    OpenUrlPubMed
  43. ↵
    Wu, J. J., A. M. Bennett. 2005. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J. Biol. Chem. 280: 16461-16466.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Seta, K. A., R. Kim, H. W. Kim, D. E. Millhorn, D. Beitner-Johnson. 2001. Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J. Biol. Chem. 276: 44405-44412.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Wong, H. R., K. E. Dunsmore, K. Page, T. P. Shanley. 2005. Heat shock-mediated regulation of MKP-1. Am. J. Physiol. 289: C1152-C1158.
    OpenUrlCrossRef
  46. ↵
    Kugler, S., S. Schuller, W. Goebel. 1997. Involvement of MAP-kinases and -phosphatases in uptake and intracellular replication of Listeria monocytogenes in J774 macrophage cells. FEMS Microbiol. Lett. 157: 131-136.
    OpenUrlCrossRefPubMed
  47. ↵
    Valledor, A. F., J. Xaus, M. Comalada, C. Soler, A. Celada. 2000. Protein kinase Cε is required for the induction of mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 164: 29-37.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Valledor, A. F., J. Xaus, L. Marques, A. Celada. 1999. Macrophage colony-stimulating factor induces the expression of mitogen-activated protein kinase phosphatase-1 through a protein kinase C-dependent pathway. J. Immunol. 163: 2452-2462.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Chi, H., S. P. Barry, R. J. Roth, J. J. Wu, E. A. Jones, A. M. Bennett, R. A. Flavell. 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. USA 103: 2274-2279.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Bokemeyer, D., A. Sorokin, M. Yan, N. G. Ahn, D. J. Templeton, M. J. Dunn. 1996. Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. J. Biol. Chem. 271: 639-642.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Liu, C., Y. Shi, Y. Du, X. Ning, N. Liu, D. Huang, J. Liang, Y. Xue, D. Fan. 2005. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp. Cell Res. 309: 410-418.
    OpenUrlCrossRefPubMed
  53. ↵
    Brondello, J. M., J. Pouyssegur, F. R. McKenzie. 1999. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286: 2514-2517.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Imasato, A., C. Desbois-Mouthon, J. Han, H. Kai, A. C. Cato, S. Akira, J. D. Li. 2002. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of Toll-like receptor 2. J. Biol. Chem. 277: 47444-47450.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Zhao, Q., E. G. Shepherd, M. E. Manson, L. D. Nelin, A. Sorokin, Y. Liu. 2005. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J. Biol. Chem. 280: 8101-8108.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Kassel, O., A. Sancono, J. Kratzschmar, B. Kreft, M. Stassen, A. C. Cato. 2001. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20: 7108-7116.
    OpenUrlAbstract
  57. ↵
    Eljaschewitsch, E., A. Witting, C. Mawrin, T. Lee, P. M. Schmidt, S. Wolf, H. Hoertnagl, C. S. Raine, R. Schneider-Stock, R. Nitsch, O. Ullrich. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79.
    OpenUrlCrossRefPubMed
  58. ↵
    Shepherd, E. G., Q. Zhao, S. E. Welty, T. N. Hansen, C. V. Smith, Y. Liu. 2004. The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages. J. Biol. Chem. 279: 54023-54031.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Hammer, M., J. Mages, H. Dietrich, A. Servatius, N. Howells, A. C. Cato, R. Lang. 2006. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J. Exp. Med. 203: 15-20.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Zhao, Q., X. Wang, L. D. Nelin, Y. Yao, R. Matta, M. E. Manson, R. S. Baliga, X. Meng, C. V. Smith, J. A. Bauer, et al 2006. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203: 131-140.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Salojin, K. V., I. B. Owusu, K. A. Millerchip, M. Potter, K. A. Platt, T. Oravecz. 2006. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 176: 1899-1907.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177: 547-550.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
    OpenUrlCrossRefPubMed
  64. ↵
    Sly, L. M., M. J. Rauh, J. Kalesnikoff, C. H. Song, G. Krystal. 2004. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21: 227-239.
    OpenUrlCrossRefPubMed
  65. ↵
    Zhang, Y., J. N. Blattman, N. J. Kennedy, J. Duong, T. Nguyen, Y. Wang, R. J. Davis, P. D. Greenberg, R. A. Flavell, C. Dong. 2004. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430: 793-797.
    OpenUrlCrossRefPubMed
  66. ↵
    Dong, C., D. D. Yang, M. Wysk, A. J. Whitmarsh, R. J. Davis, R. A. Flavell. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282: 2092-2095.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Rohan, P. J., P. Davis, C. A. Moskaluk, M. Kearns, H. Krutzsch, U. Siebenlist, K. Kelly. 1993. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science 259: 1763-1766.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Chu, Y., P. A. Solski, R. Khosravi-Far, C. J. Der, K. Kelly. 1996. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J. Biol. Chem. 271: 6497-6501.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    Givant-Horwitz, V., B. Davidson, J. M. Goderstad, J. M. Nesland, C. G. Trope, R. Reich. 2004. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 93: 517-523.
    OpenUrlCrossRefPubMed
  70. ↵
    Yin, Y., Y. X. Liu, Y. J. Jin, E. J. Hall, J. C. Barrett. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422: 527-531.
    OpenUrlCrossRefPubMed
  71. ↵
    Grumont, R. J., J. E. Rasko, A. Strasser, S. Gerondakis. 1996. Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Mol. Cell. Biol. 16: 2913-2921.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    Shen, Y. H., J. Godlewski, J. Zhu, P. Sathyanarayana, V. Leaner, M. J. Birrer, A. Rana, G. Tzivion. 2003. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J. Biol. Chem. 278: 26715-26721.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    Shen, Y., R. Luche, B. Wei, M. L. Gordon, C. D. Diltz, N. K. Tonks. 2001. Activation of the Jnk signaling pathway by a dual-specificity phosphatase, JSP-1. Proc. Natl. Acad. Sci. USA 98: 13613-13618.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    Chen, A. J., G. Zhou, T. Juan, S. M. Colicos, J. P. Cannon, M. Cabriera-Hansen, C. F. Meyer, R. Jurecic, N. G. Copeland, D. J. Gilbert, et al 2002. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J. Biol. Chem. 277: 36592-36601.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    Kolch, W.. 2005. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6: 827-837.
    OpenUrlCrossRefPubMed
  76. ↵
    Pouyssegur, J., P. Lenormand. 2003. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur. J. Biochem. 270: 3291-3299.
    OpenUrlPubMed
  77. ↵
    Saccani, S., S. Pantano, G. Natoli. 2002. p38-Dependent marking of inflammatory genes for increased NFκB recruitment. Nat. Immunol. 3: 69-75.
    OpenUrlCrossRefPubMed
  78. ↵
    Kovarik, P., D. Stoiber, P. A. Eyers, R. Menghini, A. Neininger, M. Gaestel, P. Cohen, T. Decker. 1999. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. Proc. Natl. Acad. Sci. USA 96: 13956-13961.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    Katsoulidis, E., Y. Li, H. Mears, L. C. Platanias. 2005. The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J. Interferon Cytokine Res. 25: 749-756.
    OpenUrlCrossRefPubMed
  80. ↵
    Liu, D., J. Scafidi, A. E. Prada, K. Zahedi, A. E. Davis, 3rd. 2002. Nuclear phosphatases and the proteasome in suppression of STAT1 activity in hepatocytes. Biochem. Biophys. Res. Commun. 299: 574-580.
    OpenUrlCrossRefPubMed
  81. ↵
    Venema, R. C., V. J. Venema, D. C. Eaton, M. B. Marrero. 1998. Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1. J. Biol. Chem. 273: 30795-30800.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    Slack, D. N., O. M. Seternes, M. Gabrielsen, S. M. Keyse. 2001. Distinct binding determinants for ERK2/p38α and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J. Biol. Chem. 276: 16491-16500.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 177 (11)
The Journal of Immunology
Vol. 177, Issue 11
1 Dec 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response
Roland Lang, Michael Hammer, Jörg Mages
The Journal of Immunology December 1, 2006, 177 (11) 7497-7504; DOI: 10.4049/jimmunol.177.11.7497

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response
Roland Lang, Michael Hammer, Jörg Mages
The Journal of Immunology December 1, 2006, 177 (11) 7497-7504; DOI: 10.4049/jimmunol.177.11.7497
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Down-regulation of MAPK signaling: dual specificity phosphatases (DUSP) and other MAPK phosphatases (MKP)
    • Patterns of DUSP expression: changes during development, between cell types, and in response to external stimuli
    • Defining essential functions for DUSP in immunity: the examples of DUSP1, DUSP10, and DUSP2
    • DUSP1/MKP-1: from no phenotype to molecular brake in inflammation
    • DUSP10/MKP-5: acting on innate and adaptive responses
    • DUSP2/PAC1: from feedback inhibition to driving force of inflammation
    • Inclusion of DUSP in the equation: a more accurate description of MAPK driven immune activation
    • Impact of DUSP on other signaling pathways?
    • DUSP as targets for the manipulation of immune responses?
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Dicer and PKR as Novel Regulators of Embryonic Stem Cell Fate and Antiviral Innate Immunity
  • Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease
  • Innate Immune Memory and the Host Response to Infection
Show more BRIEF REVIEWS

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606